Drugs / Melan-A analog peptide
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00160992 | Jul 2004 → Aug 2005 | melanoma | University of Lausanne Hospitals | Suspended | No outcome recorded |
| Phase 1 | NCT00112229 | Apr 2003 → Aug 2011 | melanoma | Centre Hospitalier Universitaire Vaudois | Completed | No outcome recorded |
| Phase 1 | NCT00112216 | May 1999 → Jun 2007 | melanoma | Centre Hospitalier Universitaire Vaudois | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Melan-A analog peptide | “Melan-A analog peptide + CpG and Montanide adjuvants” NCT00112229 ↗ |
| Modality | Peptide | “Three melanoma patients were immunized with a Melan-A peptide analog” PMID 12576434 ↗ Feb 2003 |
| Route | Other | “This peptide was injected together with a saponin-based adjuvant” PMID 12576434 ↗ Feb 2003 |